Systematic review to determine the prevalence of transmitted drug resistance mutations to rilpivirine in HIV-infected treatment-naive persons

Antiviral Therapy

Volumn 21, Issue 5, 2016, Pages 405-412

  Calvez, Vincent ^a   Marcelin, Anne Genevieve ^a   Vingerhoets, Johan ^b   Hill, Andrew ^c   Hadacek, Blanca ^d   Moecklinghoff, Christiane ^e  

^a SORBONNE UNIVERSITÉ   (France)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

^c MetaVirology Ltd   (United Kingdom)

^d Janssen EMEA   (France)

^e Janssen EMEA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RILPIVIRINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

AFRICA SOUTH OF THE SAHARA; ANTIVIRAL RESISTANCE; BRAZIL; CARIBBEAN; EUROPE; GENE MUTATION; GENOTYPE; GEOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE A; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE C; HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 SUBTYPE F; INDIA; PREVALENCE; PRIORITY JOURNAL; REVIEW; SOUTH AND CENTRAL AMERICA; SYSTEMATIC REVIEW; DRUG EFFECTS; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSMISSION; VIROLOGY;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; OBSERVATIONAL STUDIES AS TOPIC; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REVERSE TRANSCRIPTASE INHIBITORS; RILPIVIRINE;

EID: 84991475834     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP3024     Document Type: Review

References (22)

1. Mocroft A, Vella S, Benield T, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725-1730.
2. Gilks CF, Crowley S, Ekpini R, et al. The WHO publichealth approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368:505-510.
3. Gupta RK, Jordan M, Sultan B, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resourcelimited settings: a global collaborative study and metaregression analysis. Lancet 2012; 380:1250-1258.
4. Booth C. Chapter 10 Transmitted resistance. In Geretti A (editor). Antiretroviral resistance in clinical practice. London: Mediscript, 2006.
5. Little SJ, Holte S, Routy J, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-394.
6. World Health Organization. WHO HIV drug resistance report 2012. Switzerland, Geneva: WHO 2012. (Accessed 1 June 2015.) Available from www. who. int/hiv/pub/drugresistance/report2012/en
7. Ripamonti D, Bombana E, Rizzi M. Rilpivirine: drug proile of a second-generation non-nucleoside reverse transcriptase HIV-inhibitor. Expert Rev Anti Infect Ther 2014; 12:13-29.
8. Cohen CJ, Molina J, Cassetti I, et al. Week 96 eficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS 2013; 27:939-950.
9. Behrens G, Rijinders B, Nelson M, et al. Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected patients with HIV-1 RNA =100, 000 copies/ml: week 96 pooled ECHO/THRIVE subanalysis. AIDS Patient Care STDS 2014; 28:168-175.
10. Das K, Bauman J, Clark AJ, et al. High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic lexibility explains potency against resistance mutations. Proc Natl Acad Sci U S A 2008; 105:1466-1471.
11. Porter DP, Kulkarni R, Fralich T, Miller M, White K. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects. HIV Clin Trials 2015; 16:30-38.
12. Parczewski M. Rilpivirine in the light of the genotypic drug resistance data. HIV & AIDS Review 2013; 12:89-92.
13. Wensing AM, Calvez V, Gunthard H, et al. 2014 Update of the drug resistance mutations in HIV-1. Top Antivir Med 2014; 22:642-650.
14. Rhee SY, Gonzales M, Kantor R, Betts B, Ravela J, Shafer R. Human immunodeiciency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2003; 31:298-303.
15. United Nations. Composition of macro geographical (continental) regions, geographical sub-regions, and selected economic and other groupings. 2013. (Accessed 5 June 2015.) Available from http://unstats. un. org/unsd/methods/m49/m49regin. htm
16. World Bank. Regions. 2015. (Accessed 4 June 2015.) Available from www. worldbank. org/en/about/annualreport/regions
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188.
18. Rücker G, Schwarzer G, Carpenter J, Olkin I. Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta-analysis with zero cells. Stat Med 2009; 28:721-738.
19. Buonaguro L, Tornesello ML, Buonaguro FM. Human immunodeiciency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J Virol 2007; 81:10209-10219.
20. Rimsky L, Vingerhoets J, Van Eygen V, et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the Phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Deic Syndr 2012; 59:39-46.
21. Kulkarni R, Babaoglu K, Lansdon E, et al. The HIV-1 reverse transcriptase M184I mutation enhances the E138Kassociated resistance to rilpivirine and decreases viral itness. J Acquir Immune Deic Syndr 2012; 59:47-54.
22. Xu HT, Colby-Germinario S, Asahchop E, et al. Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on deining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine. Antimicrob Agents Chemother 2013; 57:3100-3109.